COVID-19 Response: Local Logistics     National Effort       

Monolith-based Pseudo-bioaffinity Purification Methods for Factor VIII

You are here

COVID-19 Response: Local Logistics     National Effort

Monolith-based Pseudo-bioaffinity Purification Methods for Factor VIII from Various Sources and Applications Thereof

The Novel Technology:

 
The novel technology relates to the purification of Factor VIII protein and/or its fragments from various sources by employing various pseudobioaffinity based purification methods (Histidine Ligand Affinity Chromatography –HLAC coupled with monolith-based Convective Interaction Media – CIM).
 
Applications: 
  • To use for the purification of:
  • native factor VIII from plasma cryoprecipitate,
  • recombinant B-domain deleted factor VIII:C expressed in various host systems,
  • recombinant factor VIII mutant having improved activity and stability, and
  • recombinant FVIII expressed in Pichia pastoris
Advantages:
  • No column packing or clogging problem
  • Flow independent specific binding
  • Mild elusion avoids any denaturation process of the target protein 
  • Minimal processing time and high throughput steps in comparison to classical affinity-based purification techniques to recover Factor VIII:C
  • Purified without any significant loss of activity
  • Increase in recovery yield and increase in purity
Business Model:
 
The technology is in early stage of development. Looking for potential licensee(s) interested in taking the technology to next step of development. There is a possibility of getting FDA approval and supply of chromatographic system by the producer. 
 
Principal Investigator(s): Prof. M. A. Vijiyalakhsmi, CBST
 
Invention ID: CMP-029
 
IP status: Patent Pending
 
Jurisdictions: India (IN), United States (US), Europe (EP) 
 
For more details, please write to: 
techtransfer @ ccamp.res.in